BioSpace News Archive

Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences.

Applied UV Inc. (NASDAQ: AUVI), a pioneer in UV disinfection technology, is elated to announce today that the United States Patent and Trademark Office (USPTO) issued a patent US 2023/0059472 A1 for the Company’s Airo™ Vortex, encompassing advanced disinfection capabilities and Photocatalytic Oxidation (PCO).

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, November 1, 2023, at 8:30 AM ET to discuss results for the third quarter 2023 and provide a business outlook for remainder of the year.

Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. announced they have reached an agreement to jointly develop, manufacture, and commercialize live vaccines against herpes simplex viruses.

ImmPACT Bio USA , Inc. today announced that it will participate in the 2023 Truist Securities BioPharma Symposium, to be held from November 8-9, 2023.

Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced that the Company’s management team will present and participate in one-on-one meetings at the following investor conferences.

Apogee Therapeutics, Inc. today announced that management will present at the following upcoming investor conferences.

NovelMed Therapeutics is excited to announce the commencement of its Phase II clinical trial targeting treatment-naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) patients with its groundbreaking anti-Bb antibody, NM8074.

Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2023.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced alignment with the U.S. Food and Drug Administration (FDA) on a plan to lift the clinical hold on the Phase 1/2 INGLAXA clinical trial in the United States for 4D-310 for Fabry disease cardiomyopathy.